This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly mCRPCT (metastatic castration-resistant cancer). describes widely used Radium-223 and novel trend TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion growing PSMA-based therapy, we aim also to analyze most useful diag...

In recent years, radiolabeled tracers targeting prostate-specific membrane antigen (PSMA) have had a tremendous impact on prostate cancer management. Here, we report the formation of radioactive impurities formed during clinical production 177Lu-labeled PSMA-617. We provide compelling evidence that these are result spontaneous, thermally mediated condensation reaction Glu-CO-Lys moiety resultin...